Skip to main content

Advertisement

Table 1 Characteristics of clinical trials included in the meta-analysis

From: Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysis

Study and Treatment arm Trial Male (%) Mean Age(y) Etiology HBV/HCV Cirrhosis Child-Pugh A/B Albumin (g/L)
Lee (Cancer 1997) P       
   TACE(n=31)   84 52 29/2 NA NA 37
   Conservative(n=16)   81 51 13/2 NA NA 36
Luo (Ann Surg Oncol 2011) P       
   TACE(n=84)   98 45 78/- 42 NA 41
   Conservative(n=80)   91 47 70/- 35 NA 41
Niu (Med Oncol 2011) P       
   TACE(n=115)   93 46 106/- NA 88/27 37
   Conservative(n=35)   94 48 31/- NA 21/14 36
Chung (Radiology 2011) R       
   TACE(n=83)   89 55 71/4 63 57/26 36
   Conservative(n=42)   71 58 31/2 34 15/27 33
KM Kim (JGH 2009) R       
   TACE(n=149)   87 52 NA NA 106/41 NA
   TACI(n=53)   77 54 NA NA 23/29 NA
   Hepatic resection (n=19)   95 50 NA NA 17/2 NA
   Conservative(n=60)   90 53 NA NA 18/33 NA
Zhou (APJCP 2011) R       
   TACE(n=10)   100 NA 12/- 10 5/5 NA
   LT(n=12)   100 NA 10/- 9 4/6 NA
   Hepatic resection (n=69)*   96 NA 66/- 63 55/14 NA
   Conservative(n=30)   87 NA 26/- 23 9/11 NA
JH Kim (APT 2009) R       
   TACE(n=49)   90 54 37/2 36 30/17 NA
   TACI(n=61)   87 54 56/1 45 22/32 NA
Peng (Cancer 2012) R       
   TACE(n=402)   93 55 356/7 363 389/13 34
   Hepatic resection (n=201)   93 55 172/4 176 197/4 37
  1. Note: *, Two subgroups of hepatic resection with other treatments were combined. P, perspective; R, retrospective; LT: liver transplantation; NA: not available.